The Brigham and Women's Hospital, Inc.

University of Michigan

Cornell University

Ventana Medical Systems, Inc.

Dana-farber-cancer Institute Inc.

Francesca Demichelis

Mark A Rubin

Arul M Chinnaiyan

Scott Tomlins

Daniel Rhodes

Rohit Mehra

Charles Lee

Sven Perner

Xiao-Wei Sun

Michael Otter

Phillip C Miller

Gary A Pestano

Karl Eric Garsha

Ray B Nagle

Levi A Garraway

William R Sellers

Juan Miguel Mosquera

Kyung Park

Ya-Lin Chiu

Karl Garsha

Gary Anthony Pestano

In general, the presently disclosed technology relates to identification of cancer subtypes. More specifically, the technology relates to methods for determining molecular drivers of cancer and/or progression using a multivariate image data and statistical analysis of in-situ molecular markers and morphological characteristics in the same cells of a biological sample suspected of b cancer. This analysis takes place after a single acquisition that obtains the molecular and anatomic morphology data in parallel. The analysis compares specific morphological and molecular markers to known samples exhibiting particular genetic drivers of the cancer. This method provides statistical information that allows for an increased confidence in the identification of specific molecular drivers of the cancer.

Image acquisition methods for simultaneously detecting genetic rearrangement and nuclear morphology

Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.

Recurrent gene fusions in prostate cancer

Spectral imaging for measurement of nuclear pathology features in cancer cells prepared for in situ analysis

This invention relates to a triple immunostaining assay (ERG/TFF3/HMWCK) for sensitive and specific detection of prostate cancer. Positive staining for at least one of ERG or TFF3 combined with negative staining of HMWCK in a sample such as prostate tissue sample is indicative of cancer.

ERG/TFF3/HMWCK triple immunostain for detection of prostate cancer

Described are methods for identifying single nucleotide polymorphism (SNPs) that are useful for analyzing genetic samples, and for using said SNPs to determine genetic identity of samples.

Methods for identifying and using SNP panels

The present invention relates to the identification and use of gene expression profiles with clinical relevance to prostate cancer. In particular, the invention provides the identity of genes whose expression, at the transcriptional and protein levels, is correlated with prostate cancer progression. Methods and kits are described for using these gene expression profiles in the study and/or diagnosis of prostate cancer diseases, in the prediction of prostate cancer progression, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that target these genes or their protein products, in particular for the development of therapeutics for modulating prostate cancer progression.

Biomarkers for predicting prostate cancer progression

Growing community of inventors

New York, NY, United States of America

Francesca Demichelis